These studies suggest that PTEN and RAS abnormalities in T-ALL may be suitable candidates as biomarkers and assist in directing targeted therapy, but their prognostic impact in pediatric patients is unclear, particularly in relation to their NOTCH1/FBXW7 genotype. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.